These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25093008)

  • 1. Cell senescence in myxoid/round cell liposarcoma.
    Kåbjörn Gustafsson C; Ståhlberg A; Engtröm K; Danielsson A; Turesson I; Aman P
    Sarcoma; 2014; 2014():208786. PubMed ID: 25093008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.
    Engström K; Willén H; Kåbjörn-Gustafsson C; Andersson C; Olsson M; Göransson M; Järnum S; Olofsson A; Warnhammar E; Aman P
    Am J Pathol; 2006 May; 168(5):1642-53. PubMed ID: 16651630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.
    Andersson MK; Göransson M; Olofsson A; Andersson C; Aman P
    BMC Cancer; 2010 Jun; 10():249. PubMed ID: 20515481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ.
    Göransson M; Andersson MK; Forni C; Ståhlberg A; Andersson C; Olofsson A; Mantovani R; Aman P
    Oncogene; 2009 Jan; 28(2):270-8. PubMed ID: 18850010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas.
    Olofsson A; Willén H; Göransson M; Engström K; Meis-Kindblom JM; Stenman G; Kindblom LG; Aman P
    Int J Oncol; 2004 Nov; 25(5):1349-55. PubMed ID: 15492825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normal and functional TP53 in genetically stable myxoid/round cell liposarcoma.
    Ståhlberg A; Kåbjörn Gustafsson C; Engtröm K; Thomsen C; Dolatabadi S; Jonasson E; Li CY; Ruff D; Chen SM; Åman P
    PLoS One; 2014; 9(11):e113110. PubMed ID: 25393000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.
    Safavi S; Järnum S; Vannas C; Udhane S; Jonasson E; Tomic TT; Grundevik P; Fagman H; Hansson M; Kalender Z; Jauhiainen A; Dolatabadi S; Stratford EW; Myklebost O; Eriksson M; Stenman G; Schneider-Stock R; Ståhlberg A; Åman P
    Oncotarget; 2016 Jan; 7(1):433-45. PubMed ID: 26595521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DDIT3 Expression in Liposarcoma Development.
    Kåbjörn Gustafsson C; Engström K; Aman P
    Sarcoma; 2014; 2014():954671. PubMed ID: 24790523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2.
    Bento C; Andersson MK; Aman P
    BMC Cell Biol; 2009 Dec; 10():89. PubMed ID: 20017906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory mechanisms, expression levels and proliferation effects of the FUS-DDIT3 fusion oncogene in liposarcoma.
    Åman P; Dolatabadi S; Svec D; Jonasson E; Safavi S; Andersson D; Grundevik P; Thomsen C; Ståhlberg A
    J Pathol; 2016 Apr; 238(5):689-99. PubMed ID: 26865464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses.
    Svec D; Dolatabadi S; Thomsen C; Cordes N; Shannon M; Fitzpatrick P; Landberg G; Åman P; Ståhlberg A
    Lab Invest; 2018 Jul; 98(7):957-967. PubMed ID: 29588491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of translocation type in myxoid liposarcoma and identification of a novel EWSR1-DDIT3 fusion.
    Bode-Lesniewska B; Frigerio S; Exner U; Abdou MT; Moch H; Zimmermann DR
    Genes Chromosomes Cancer; 2007 Nov; 46(11):961-71. PubMed ID: 17647282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma.
    Trautmann M; Menzel J; Bertling C; Cyra M; Isfort I; Steinestel K; Elges S; Grünewald I; Altvater B; Rossig C; Fröhling S; Hafner S; Simmet T; Åman P; Wardelmann E; Huss S; Hartmann W
    Clin Cancer Res; 2017 Oct; 23(20):6227-6238. PubMed ID: 28637688
    [No Abstract]   [Full Text] [Related]  

  • 14. Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma.
    Berthold R; Isfort I; Erkut C; Heinst L; Grünewald I; Wardelmann E; Kindler T; Åman P; Grünewald TGP; Cidre-Aranaz F; Trautmann M; Fröhling S; Scholl C; Hartmann W
    Oncogenesis; 2022 Apr; 11(1):20. PubMed ID: 35459264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myxoid liposarcoma-associated EWSR1-DDIT3 selectively represses osteoblastic and chondrocytic transcription in multipotent mesenchymal cells.
    Suzuki K; Matsui Y; Higashimoto M; Kawaguchi Y; Seki S; Motomura H; Hori T; Yahara Y; Kanamori M; Kimura T
    PLoS One; 2012; 7(5):e36682. PubMed ID: 22570737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DDIT3 gene break-apart as a molecular marker for diagnosis of myxoid liposarcoma--assay validation and clinical experience.
    Narendra S; Valente A; Tull J; Zhang S
    Diagn Mol Pathol; 2011 Dec; 20(4):218-24. PubMed ID: 22089349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.
    Göransson M; Elias E; Ståhlberg A; Olofsson A; Andersson C; Aman P
    Int J Cancer; 2005 Jul; 115(4):556-60. PubMed ID: 15688424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FUS-DDIT3 Fusion Oncoprotein Expression Affects JAK-STAT Signaling in Myxoid Liposarcoma.
    Dolatabadi S; Jonasson E; Andersson L; Luna Santamaría M; Lindén M; Österlund T; Åman P; Ståhlberg A
    Front Oncol; 2022; 12():816894. PubMed ID: 35186752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The utility of fluorescence in situ hybridization (FISH) in the diagnosis of myxoid soft tissue neoplasms.
    Downs-Kelly E; Goldblum JR; Patel RM; Weiss SW; Folpe AL; Mertens F; Hartke M; Tubbs RR; Skacel M
    Am J Surg Pathol; 2008 Jan; 32(1):8-13. PubMed ID: 18162764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis.
    Oda Y; Yamamoto H; Takahira T; Kobayashi C; Kawaguchi K; Tateishi N; Nozuka Y; Tamiya S; Tanaka K; Matsuda S; Yokoyama R; Iwamoto Y; Tsuneyoshi M
    J Pathol; 2005 Dec; 207(4):410-21. PubMed ID: 16177957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.